Stockscreener 앱 받기
1.66
18.57%
0.26
시간 외 거래:
1.63
-0.03
-1.81%
전일 마감가:
$1.40
열려 있는:
$1.42
하루 거래량:
1.79M
Relative Volume:
8.33
시가총액:
$123.55M
수익:
$63.63M
순이익/손실:
$10.62M
주가수익비율:
83.00
EPS:
0.02
순현금흐름:
$-8.64M
1주 성능:
+38.33%
1개월 성능:
+52.29%
6개월 성능:
+45.61%
1년 성능:
+18.57%
1일 변동 폭
$1.40
$1.72
1주일 범위
$1.20
$1.72
52주 변동 폭
$0.8214
$1.90
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
명칭
Protalix BioTherapeutics Inc.
전화
972 4 988 9488
주소
2 Snunit Street, Science Park PO Box 455, Karmiel
PLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PLX | 1.66 | 123.55M | 63.63M | 10.62M | -8.64M | 0.02 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-17 | 재확인 | Rodman & Renshaw | Buy |
| 2016-04-04 | 개시 | Rodman & Renshaw | Buy |
| 2015-04-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2014-11-12 | 재확인 | R. F. Lafferty | Buy |
| 2014-01-24 | 개시 | R. F. Lafferty | Buy |
| 2012-05-02 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 재확인 | Oppenheimer | Outperform |
| 2012-04-30 | 다운그레이드 | Auriga | Buy → Hold |
| 2011-10-13 | 개시 | Morgan Joseph | Hold |
| 2011-03-17 | 다운그레이드 | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 재확인 | Oppenheimer | Outperform |
| 2010-10-14 | 재확인 | UBS | Buy |
| 2009-12-02 | 재확인 | Hapoalim | Outperform |
| 2009-09-22 | 개시 | Canaccord Adams | Buy |
| 2009-09-02 | 개시 | Hapoalim | Outperform |
| 2008-12-01 | 재확인 | Oppenheimer | Outperform |
| 2008-03-11 | 개시 | UBS | Buy |
| 2007-11-20 | 개시 | CIBC Wrld Mkts | Sector Outperform |
모두보기
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease - Yahoo Finance
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Protalix: Q3 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Reports Strong Q3 2024 Results - TipRanks
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results - citybiz
Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report - Quartzy
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 - The Malaysian Reserve
Protalix BioTherapeutics Sets Q3 2024 Earnings Call for November 14 | PLX Stock News - StockTitan
Accolade And 2 Other Penny Stocks To Watch On US Exchanges - Simply Wall St
Fabry Disease Market to grow at a CAGR of ~6% by 2032, analyzes - openPR
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GuruFocus.com
Protalix BioTherapeutics Announces Repayment of Outstanding Seni - GuruFocus.com
PLXProtalix BioTherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 - PR Newswire
OTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCR - Zacks Small Cap Research
Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 - GlobeNewswire
Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes - Kilgore News Herald
Is Protalix BioTherapeutics Inc. (PLX) worth investing in despite its overvalued state? - US Post News
Protalix BioTherapeutics Inc. (PLX) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? - Yahoo Finance UK
Protalix BioTherapeutics clears debt, secures operational runway - Investing.com
Protalix BioTherapeutics clears debt, secures operational runway By Investing.com - Investing.com Canada
Protalix says FDA okays drug-trial design - Reuters
10 Best Rated Penny Stocks To Buy According to Analysts - Insider Monkey
Protalix BioTherapeutics, Inc. Expected to Post FY2024 Earnings of $0.06 Per Share (NYSE:PLX) - MarketBeat
Fabry Disease Market to Sour at a CAGR of ~6% by 2032, estimates - openPR
Analyzing Protalix BioTherapeutics (NYSE:PLX) & Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World
Protalix BioTherapeutics, Inc. to Post FY2024 Earnings of $0.06 Per Share, Zacks Small Cap Forecasts (NYSE:PLX) - Defense World
PLX: A Focus on Renal Rare Disease - Yahoo Finance
Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022 - BioSpace
Protalix BioTherapeutics (NYSE:PLX) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS - Defense World
Protalix BioTherapeutics (NYSE:PLX) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat
Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021 - BioSpace
Protalix BioTherapeutics Inc (PLX) Q2 2024 Earnings Call Transcr - GuruFocus.com
Protalix BioTherapeutics Inc. (PLX) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Earnings call: Protalix reports progress on PRX-115 and stable finances - Investing.com Australia
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2024 Earnings Call Transcript - Insider Monkey
Financial Health Report: Protalix BioTherapeutics Inc. (PLX)’s Ratios Tell a Tale - The Dwinnex
Protalix: Q2 Earnings Snapshot - Darien Times
Protalix BioTherapeutics to Present at the 2024 BIO International Convention - Longview News-Journal
Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 - Longview News-Journal
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Protalix BioTherapeutics Inc. (PLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):